Enzychem Lifesciences Corporation (183490.KQ) KOE
990.00
-27(-2.65%)
Currency In KRW
- General
- Statistics
- Historical Data
- Profile
- Financials
Enzychem Lifesciences Corporation
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
122
First IPO Date
April 05, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Ki-Young Sohn | Chairman & Chief Executive Officer | 0 | N/A |
| Jeff Clark | Chief Licensing Officer | 0 | N/A |
| Jae-Yong Lee | Vice President & Executive Director | 0 | N/A |
| John Choi | Executive Director | 0 | N/A |
| G. Alexander Fleming | Member of Corporate Advisory Committee & Chief Technology Officer | 0 | N/A |
| Do-Young Lee | Chief Scientific Officer & Member of the Board of Directors | 0 | N/A |
| Myung-Hwan Kim | CMO & Director | 0 | N/A |
Description
Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.
